课题基金 / 基金详情

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM

CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM
核心——临床试验方案审查和监测系统
批准号:
6563724
负责人:
JOHN A GLASPY
金额:
$16.72万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-12-01 至 2002-11-30

项目摘要

项目成果

JOHN A GLASPY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Description: The Internal Scientific Protocol Review Committee, chaired by Dr. John A. Glaspy, was approved conditionally for early peer reevaluation during the last review. Two peer review evaluations occurred during the interim at the Parent Committee level. The first resulted in disapproval; the second awarded approval for the ISPRC process. The key elements at that time were a memo from the Chancellor indicating that all cancer-related research done at UCLA needed to have approval of the ISPRC for scientific merit prior to its submission to the IRB and evidence of more rigorous committee function. In addition, expanded committee membership, including a broader range of oncology disciplines and oncology research, had been instituted. A statistical checkoff had also been established to assure that all protocols have been seen by Cancer Center biostatisticians prior to their submission. The present application provides evidence that all protocols are being reapproved annually after re-review prior to the IRB submission. The committee now consists of 11 members representing biostatistics, cancer control, pharmacy, research nursing, and a spectrum of oncologists. For new protocol submissions, the committee uses a standard set of criteria. Most disapprovals over the past year are based upon one of the following: 1) insufficient scientific merit; 2) inadequate biostatistical analytical sections; 3) overlap with existing protocols without an obvious need for the secondary protocol; and 4) inability to support and carry out the protocol due to lack of adequate resources. With respect to the annual renewal, most disapprovals of those continuations were based upon one of the following: the rate of accrual is substantially lower than the originally stated target; the total accrual has met the originally stated target; or a report of the Quality Control Committee of any of the investigator's studies indicating that the research has not been conducted in a fashion that will lead to generation of correct and valid conclusions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Resource for Minority Patient Recruitment
Women's Cancers
CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEM
CORE--CLINICAL MATERIAL/PROTOCOLS
海外基金